Literature DB >> 24975371

A method for selection of beam angles robust to intra-fractional motion in proton therapy of lung cancer.

Oscar Casares-Magaz1, Jakob Toftegaard, Ludvig P Muren, Jesper F Kallehauge, Niels Bassler, Per R Poulsen, Jørgen B B Petersen.   

Abstract

BACKGROUND: Proton therapy offers the potential for sparing the normal tissue surrounding the target. However, due to well-defined proton ranges around the Bragg peak, dose deposition is more sensitive to changes in the water equivalent path length (WEPL) than with photons. In this study, we assess WEPL variations caused by breathing-induced motion for all possible beam angles in a series of lung cancer patients. By studying the association between measures for WEPL variation and breathing-induced target dose degradation we aimed to develop and explore a tool to identify beam angles that are robust to patient-specific patterns of intra-fractional motion.
MATERIAL AND METHODS: Using four-dimensional computed tomography (4DCT) images of three lung cancer patients we evaluated the impact of the WEPL changes on target dose coverage for a series of coplanar single-beam plans. The plans were optimised for the internal target volume (ITV) at the maximum intensity projection (MIP) CT for every 3° gantry interval. The plans were transferred to the ten 4DCT phases and the average reduction in ITV V₉₅ over the ten phases, relative to the original MIP CT calculation, was quantified. The target dose reduction was associated with the mean difference between the WEPL and the phase-averaged WEPL computed for all beam rays across all possible gantry-couch angle combinations.
RESULTS: The gantry-couch angle maps showed areas of both high and low WEPL variation, with overall quite similar patterns yet with individual differences reflecting differences in tumour position and breathing-induced motion. The coplanar plans showed a strong association between WEPL changes and ITV V₉₅ reduction, with a correlation coefficient ranging between 0.92 and 0.98 for the three patients (p < 0.01).
CONCLUSION: We have presented a 4DCT-based method to quantify WEPL changes during the breathing cycle. The method identified proton field gantry-couch angle combinations that were either sensitive or robust to WEPL changes. WEPL variations along the beam path were associated with target under-dosage.

Entities:  

Mesh:

Year:  2014        PMID: 24975371     DOI: 10.3109/0284186X.2014.927586

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  5 in total

1.  On-line dose-guidance to account for inter-fractional motion during proton therapy.

Authors:  Kia Busch; Ludvig P Muren; Sara Thörnqvist; Andreas G Andersen; Jesper Pedersen; Lei Dong; Jørgen B B Petersen
Journal:  Phys Imaging Radiat Oncol       Date:  2018-12-19

2.  Treatment plan comparison of proton vs photon radiotherapy for lower-grade gliomas.

Authors:  Camilla S Byskov; Christian R Hansen; Rikke H Dahlrot; Lene Haldbo-Classen; Charlotte A Haslund; Flemming Kjær-Kristoffersen; Thomas O Kristensen; Yasmin Lassen-Ramshad; Slávka Lukacova; Aida Muhic; Petra W Nyström; Britta Weber; Jesper F Kallehauge
Journal:  Phys Imaging Radiat Oncol       Date:  2021-11-28

3.  Proton Beam Therapy versus Photon Radiotherapy for Stage I Non-Small Cell Lung Cancer.

Authors:  Yang-Gun Suh; Jae Myoung Noh; Doo Yeul Lee; Tae Hyun Kim; Unurjargal Bayasgalan; Hongryull Pyo; Sung Ho Moon
Journal:  Cancers (Basel)       Date:  2022-07-26       Impact factor: 6.575

4.  A Beam-Angle-Selection Method to Improve Inter-Fraction Motion Robustness for Lung Tumor Irradiation With Passive Proton Scattering.

Authors:  Yawei Zhang; Meng Wei Ho; Zuofeng Li
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

5.  AAPM Task Group Report 290: Respiratory motion management for particle therapy.

Authors:  Heng Li; Lei Dong; Christoph Bert; Joe Chang; Stella Flampouri; Kyung-Wook Jee; Liyong Lin; Michael Moyers; Shinichiro Mori; Joerg Rottmann; Erik Tryggestad; Sastry Vedam
Journal:  Med Phys       Date:  2022-01-31       Impact factor: 4.506

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.